ProPhase Labs, Inc. (PRPH)
USD 0.29
(2.28%)
USD 0.29
(2.28%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -16.78 Million USD | -190.9% |
| 2022 | 18.46 Million USD | 194.32% |
| 2021 | 6.27 Million USD | 359.21% |
| 2020 | -2.42 Million USD | 19.68% |
| 2019 | -3.01 Million USD | -73.16% |
| 2018 | -1.74 Million USD | -104.16% |
| 2017 | 41.83 Million USD | 1558.54% |
| 2016 | -2.86 Million USD | 20.33% |
| 2015 | -3.6 Million USD | 54.05% |
| 2014 | -7.83 Million USD | -2034.32% |
| 2013 | 405 Thousand USD | 137.12% |
| 2012 | -1.09 Million USD | 59.74% |
| 2011 | -2.71 Million USD | 22.59% |
| 2010 | -3.5 Million USD | 8.88% |
| 2009 | -3.84 Million USD | 30.58% |
| 2008 | -5.53 Million USD | -125.12% |
| 2007 | -2.45 Million USD | -40.61% |
| 2006 | -1.74 Million USD | -154.35% |
| 2005 | 3.21 Million USD | 610.3% |
| 2004 | 452.86 Thousand USD | -32.87% |
| 2003 | 674.57 Thousand USD | 110.45% |
| 2002 | -6.45 Million USD | -3088.67% |
| 2001 | 215.96 Thousand USD | 104.16% |
| 2000 | -5.19 Million USD | -23.73% |
| 1999 | -4.2 Million USD | -161.76% |
| 1998 | 6.8 Million USD | -67.62% |
| 1997 | 21 Million USD | 3100.0% |
| 1996 | -700 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -6.15 Million USD | 1.79% |
| 2024 Q1 | -6.26 Million USD | 28.41% |
| 2023 Q1 | 550 Thousand USD | 122.5% |
| 2023 Q4 | -8.75 Million USD | -70.22% |
| 2023 FY | -16.78 Million USD | -190.9% |
| 2023 Q3 | -5.14 Million USD | -49.45% |
| 2023 Q2 | -3.44 Million USD | -725.45% |
| 2022 FY | 18.46 Million USD | 194.32% |
| 2022 Q4 | -2.44 Million USD | -352.48% |
| 2022 Q3 | 968 Thousand USD | -87.0% |
| 2022 Q2 | 7.44 Million USD | -40.4% |
| 2022 Q1 | 12.49 Million USD | 17.99% |
| 2021 Q4 | 10.58 Million USD | 366.19% |
| 2021 FY | 6.27 Million USD | 359.21% |
| 2021 Q2 | -1.39 Million USD | -231.98% |
| 2021 Q1 | 1.05 Million USD | 208.08% |
| 2021 Q3 | -3.97 Million USD | -185.16% |
| 2020 Q4 | -978 Thousand USD | -139.71% |
| 2020 Q1 | -809 Thousand USD | -73.23% |
| 2020 Q3 | -408 Thousand USD | -682.86% |
| 2020 Q2 | 70 Thousand USD | 108.65% |
| 2020 FY | -2.42 Million USD | 19.68% |
| 2019 Q4 | -467 Thousand USD | -9.11% |
| 2019 FY | -3.01 Million USD | -73.16% |
| 2019 Q3 | -428 Thousand USD | 65.43% |
| 2019 Q2 | -1.23 Million USD | -22.21% |
| 2019 Q1 | -1.01 Million USD | -116.92% |
| 2018 Q2 | -260 Thousand USD | -704.65% |
| 2018 FY | -1.74 Million USD | -104.16% |
| 2018 Q1 | 43 Thousand USD | -84.36% |
| 2018 Q3 | -1.05 Million USD | -306.54% |
| 2018 Q4 | -467 Thousand USD | 55.82% |
| 2017 Q3 | -777 Thousand USD | 66.29% |
| 2017 Q2 | -2.3 Million USD | -105.25% |
| 2017 Q4 | 275 Thousand USD | 135.39% |
| 2017 Q1 | 43.88 Million USD | 7772.73% |
| 2017 FY | 41.83 Million USD | 1558.54% |
| 2016 Q3 | 167 Thousand USD | 114.82% |
| 2016 Q2 | -1.12 Million USD | 15.64% |
| 2016 Q4 | -572 Thousand USD | -442.51% |
| 2016 Q1 | -1.33 Million USD | -6.37% |
| 2016 FY | -2.86 Million USD | 20.33% |
| 2015 Q4 | -1.25 Million USD | -308.64% |
| 2015 Q3 | 602 Thousand USD | 138.44% |
| 2015 Q1 | -1.38 Million USD | -104.14% |
| 2015 FY | -3.6 Million USD | 54.05% |
| 2015 Q2 | -1.56 Million USD | -13.48% |
| 2014 FY | -7.83 Million USD | -2034.32% |
| 2014 Q1 | -804 Thousand USD | -234.45% |
| 2014 Q2 | -3.13 Million USD | -290.3% |
| 2014 Q3 | -3.21 Million USD | -2.49% |
| 2014 Q4 | -676 Thousand USD | 78.98% |
| 2013 Q3 | 1.23 Million USD | 171.9% |
| 2013 Q2 | -1.71 Million USD | -692.76% |
| 2013 Q1 | 290 Thousand USD | -35.84% |
| 2013 FY | 405 Thousand USD | 137.12% |
| 2013 Q4 | 598 Thousand USD | -51.62% |
| 2012 Q3 | 1.07 Million USD | 155.65% |
| 2012 Q1 | -688 Thousand USD | 62.47% |
| 2012 Q4 | 452 Thousand USD | -57.91% |
| 2012 Q2 | -1.93 Million USD | -180.52% |
| 2012 FY | -1.09 Million USD | 59.74% |
| 2011 Q3 | 1.11 Million USD | 213.96% |
| 2011 Q1 | -1.01 Million USD | 10.43% |
| 2011 Q2 | -974 Thousand USD | 3.85% |
| 2011 FY | -2.71 Million USD | 22.59% |
| 2011 Q4 | -1.83 Million USD | -265.14% |
| 2010 Q1 | -1.06 Million USD | -159.63% |
| 2010 Q3 | 947 Thousand USD | 142.01% |
| 2010 FY | -3.5 Million USD | 8.88% |
| 2010 Q4 | -1.13 Million USD | -219.43% |
| 2010 Q2 | -2.25 Million USD | -112.24% |
| 2009 Q2 | -4.62 Million USD | -110.31% |
| 2009 FY | -3.84 Million USD | 30.58% |
| 2009 Q1 | -2.19 Million USD | -11.9% |
| 2009 Q4 | 1.78 Million USD | 48.17% |
| 2009 Q3 | 1.2 Million USD | 125.99% |
| 2008 Q4 | -1.96 Million USD | -323.55% |
| 2008 Q3 | 879.1 Thousand USD | 130.54% |
| 2008 Q1 | -1.56 Million USD | -194.5% |
| 2008 Q2 | -2.87 Million USD | -83.42% |
| 2008 FY | -5.53 Million USD | -125.12% |
| 2007 Q3 | 1.32 Million USD | 137.75% |
| 2007 FY | -2.45 Million USD | -40.61% |
| 2007 Q1 | -1.92 Million USD | -254.8% |
| 2007 Q2 | -3.51 Million USD | -82.54% |
| 2007 Q4 | 1.66 Million USD | 24.98% |
| 2006 Q3 | 1.07 Million USD | 141.2% |
| 2006 FY | -1.74 Million USD | -154.35% |
| 2006 Q4 | 1.24 Million USD | 15.48% |
| 2006 Q2 | -2.61 Million USD | -80.04% |
| 2006 Q1 | -1.45 Million USD | -167.23% |
| 2005 Q1 | -154.49 Thousand USD | -107.84% |
| 2005 Q2 | -1.79 Million USD | -1058.88% |
| 2005 FY | 3.21 Million USD | 610.3% |
| 2005 Q3 | 2.99 Million USD | 267.48% |
| 2005 Q4 | 2.16 Million USD | -27.86% |
| 2004 Q3 | 177.37 Thousand USD | 119.44% |
| 2004 Q1 | -781.63 Thousand USD | -130.75% |
| 2004 Q2 | -912.47 Thousand USD | -16.74% |
| 2004 Q4 | 1.96 Million USD | 1010.41% |
| 2004 FY | 452.86 Thousand USD | -32.87% |
| 2003 Q4 | 2.54 Million USD | 1795.3% |
| 2003 Q2 | -1.05 Million USD | -11.47% |
| 2003 Q3 | 134.12 Thousand USD | 112.71% |
| 2003 FY | 674.57 Thousand USD | 110.45% |
| 2003 Q1 | -946.56 Thousand USD | 66.23% |
| 2002 Q2 | -1.45 Million USD | 14.73% |
| 2002 Q4 | -2.8 Million USD | -460.17% |
| 2002 Q3 | -500.39 Thousand USD | 65.5% |
| 2002 Q1 | -1.7 Million USD | -272.54% |
| 2002 FY | -6.45 Million USD | -3088.67% |
| 2001 Q3 | 313.61 Thousand USD | 146.09% |
| 2001 FY | 215.96 Thousand USD | 104.16% |
| 2001 Q1 | -402.9 Thousand USD | -252.12% |
| 2001 Q2 | -680.44 Thousand USD | -68.88% |
| 2001 Q4 | 985.7 Thousand USD | 214.3% |
| 2000 Q4 | 264.85 Thousand USD | 131.51% |
| 2000 FY | -5.19 Million USD | -23.73% |
| 2000 Q3 | 114.4 Thousand USD | 106.92% |
| 2000 Q2 | -1.65 Million USD | 57.89% |
| 2000 Q1 | -3.92 Million USD | -201.8% |
| 1999 FY | -4.2 Million USD | -161.76% |
| 1999 Q1 | -1.9 Million USD | -176.0% |
| 1999 Q2 | -1.1 Million USD | 42.11% |
| 1999 Q3 | 400 Thousand USD | 136.36% |
| 1999 Q4 | -1.3 Million USD | -425.0% |
| 1998 Q4 | 2.5 Million USD | -16.67% |
| 1998 Q1 | 1.3 Million USD | -85.71% |
| 1998 Q3 | 3 Million USD | 0.0% |
| 1998 FY | 6.8 Million USD | -67.62% |
| 1998 Q2 | - USD | -100.0% |
| 1997 Q1 | 6.5 Million USD | 286.9% |
| 1997 Q4 | 9.1 Million USD | 106.82% |
| 1997 Q2 | 1.1 Million USD | -83.08% |
| 1997 FY | 21 Million USD | 3100.0% |
| 1997 Q3 | 4.4 Million USD | 300.0% |
| 1996 FY | -700 Thousand USD | 0.0% |
| 1996 Q4 | 1.68 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 48.15 Million USD | 134.85% |
| China SXT Pharmaceuticals, Inc. | -3.09 Million USD | -441.611% |
| Embecta Corp. | 70.4 Million USD | 123.838% |
| Pacira BioSciences, Inc. | 41.95 Million USD | 140.0% |
| PainReform Ltd. | -9.34 Million USD | -79.602% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | -272.433% |
| SCYNEXIS, Inc. | 67.04 Million USD | 125.032% |
| Journey Medical Corporation | -3.85 Million USD | -335.557% |
| Safety Shot Inc | -15.08 Million USD | -11.264% |
| Alpha Teknova, Inc. | -36.78 Million USD | 54.372% |
| Bright Green Corporation | -13.12 Million USD | -27.837% |
| Procaps Group, S.A. | 42.54 Million USD | 139.45% |
| Alvotech | -551.73 Million USD | 96.958% |
| ANI Pharmaceuticals, Inc. | 18.77 Million USD | 189.366% |
| Aquestive Therapeutics, Inc. | -7.87 Million USD | -113.24% |
| Cosmos Health Inc. | -18.54 Million USD | 9.495% |
| Dynavax Technologies Corporation | -6.38 Million USD | -162.67% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 91.98% |
| Intra-Cellular Therapies, Inc. | -139.67 Million USD | 87.985% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | -272.433% |
| Theratechnologies Inc. | -23.95 Million USD | 29.949% |
| Harrow Health, Inc. | -24.41 Million USD | 31.252% |
| Sonoma Pharmaceuticals, Inc. | -4.83 Million USD | -247.094% |
| Biofrontera Inc. | -20.13 Million USD | 16.636% |
| DURECT Corporation | -27.62 Million USD | 39.248% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 1375.228% |
| Cronos Group Inc. | -73.96 Million USD | 77.31% |
| OptiNose, Inc. | -35.48 Million USD | 52.704% |
| Ironwood Pharmaceuticals, Inc. | -1 Billion USD | 98.326% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | 60.231% |
| RedHill Biopharma Ltd. | 23.91 Million USD | 170.171% |
| Organogenesis Holdings Inc. | 4.94 Million USD | 439.373% |
| Guardion Health Sciences, Inc. | 158.03 Thousand USD | 10719.301% |
| Cumberland Pharmaceuticals Inc. | -6.27 Million USD | -167.258% |
| Radius Health, Inc. | -25.79 Million USD | 34.931% |
| Universe Pharmaceuticals INC | -6.16 Million USD | -172.3% |
| Phibro Animal Health Corporation | 2.41 Million USD | 794.619% |
| Procaps Group S.A. | 42.54 Million USD | 139.45% |
| TherapeuticsMD, Inc. | -10.27 Million USD | -63.281% |
| Viatris Inc. | 54.7 Million USD | 130.68% |
| Rockwell Medical, Inc. | -8.43 Million USD | -98.862% |
| Aytu BioPharma, Inc. | -15.84 Million USD | -5.92% |
| SIGA Technologies, Inc. | 68.06 Million USD | 124.654% |
| Tilray Brands, Inc. | -244.98 Million USD | 93.15% |
| Lifecore Biomedical, Inc. | 12.01 Million USD | 239.699% |
| Shineco, Inc. | -22.44 Million USD | 25.244% |
| PetIQ, Inc. | 2.13 Million USD | 887.518% |
| Regencell Bioscience Holdings Limited | -4.3 Million USD | -290.112% |
| Incannex Healthcare Limited | -18.45 Million USD | 9.085% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 106.721% |
| Alimera Sciences, Inc. | -20.13 Million USD | 16.64% |
| Silver Spike Investment Corp. | 7.34 Million USD | 328.634% |
| Assertio Holdings, Inc. | -331.94 Million USD | 94.944% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6.59 Million USD | -154.553% |
| Petros Pharmaceuticals, Inc. | -8.16 Million USD | -105.581% |
| Clever Leaves Holdings Inc. | -17.89 Million USD | 6.241% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 16.33% |
| Avadel Pharmaceuticals plc | -160.27 Million USD | 89.529% |
| Hempacco Co., Inc. | -13.12 Million USD | -27.852% |
| Talphera, Inc. | -18.39 Million USD | 8.779% |
| Alvotech | -551.73 Million USD | 96.958% |
| Eagle Pharmaceuticals, Inc. | 35.64 Million USD | 147.085% |
| Lantheus Holdings, Inc. | 326.66 Million USD | 105.137% |
| Currenc Group, Inc. | -15.3 Million USD | -9.639% |
| Kamada Ltd. | 8.28 Million USD | 302.583% |
| Indivior PLC | 2 Million USD | 939.1% |
| Evoke Pharma, Inc. | -7.79 Million USD | -115.367% |
| Flora Growth Corp. | -57.03 Million USD | 70.576% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 16.33% |
| Evolus, Inc. | -61.68 Million USD | 72.794% |
| HUTCHMED (China) Limited | 100.78 Million USD | 116.652% |
| Amphastar Pharmaceuticals, Inc. | 137.54 Million USD | 112.201% |
| Akanda Corp. | -32.27 Million USD | 48.003% |